186 related articles for article (PubMed ID: 25921126)
1. Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer.
Ekin RG; Akarken I; Cakmak O; Tarhan H; Celik O; Ilbey YO; Divrik RT; Zorlu F
Asian Pac J Cancer Prev; 2015; 16(8):3241-5. PubMed ID: 25921126
[TBL] [Abstract][Full Text] [Related]
2. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
[TBL] [Abstract][Full Text] [Related]
3. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
4. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer.
Sousa A; Piñeiro I; Rodríguez S; Aparici V; Monserrat V; Neira P; Carro E; Murias C; Uribarri C
Int J Hyperthermia; 2016 Jun; 32(4):374-80. PubMed ID: 26915466
[TBL] [Abstract][Full Text] [Related]
5. Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.
Geijsen ED; de Reijke TM; Koning CC; Zum Vörde Sive Vörding PJ; de la Rosette JJ; Rasch CR; van Os RM; Crezee J
J Urol; 2015 Nov; 194(5):1202-8. PubMed ID: 26143111
[TBL] [Abstract][Full Text] [Related]
6. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.
Xylinas E; Kent M; Dabi Y; Rieken M; Kluth LA; Al Hussein Al Awamlh B; Ouzaid I; Pycha A; Comploj E; Svatek RS; Lotan Y; Karakiewicz PI; Holmang S; Shariat SF
Urol Oncol; 2018 Mar; 36(3):89.e1-89.e5. PubMed ID: 29221642
[TBL] [Abstract][Full Text] [Related]
7. Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression.
Maffezzini M; Campodonico F; Canepa G; Manuputty EE; Tamagno S; Puntoni M
Cancer Chemother Pharmacol; 2014 May; 73(5):925-30. PubMed ID: 24585046
[TBL] [Abstract][Full Text] [Related]
8. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
Arends TJ; van der Heijden AG; Witjes JA
J Urol; 2014 Sep; 192(3):708-13. PubMed ID: 24704017
[TBL] [Abstract][Full Text] [Related]
9. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.
Colombo R; Da Pozzo LF; Salonia A; Rigatti P; Leib Z; Baniel J; Caldarera E; Pavone-Macaluso M
J Clin Oncol; 2003 Dec; 21(23):4270-6. PubMed ID: 14581436
[TBL] [Abstract][Full Text] [Related]
10. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
11. Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG?
Badalato GM; Hruby G; Razmjoo M; McKiernan JM
Can J Urol; 2011 Oct; 18(5):5890-5. PubMed ID: 22018151
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
13. Intravesical therapy for superficial bladder cancer: slow but steady progress.
Lamm DL
J Clin Oncol; 2003 Dec; 21(23):4259-60. PubMed ID: 14581444
[No Abstract] [Full Text] [Related]
14. Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
Gözen AS; Umari P; Scheitlin W; Su FE; Akin Y; Rassweiler J
Arch Ital Urol Androl; 2017 Jun; 89(2):102-105. PubMed ID: 28679178
[TBL] [Abstract][Full Text] [Related]
15. The role of hyperthermia as a treatment for non-muscle invasive bladder cancer.
Bahouth Z; Halachmi S; Moskovitz B; Nativ O
Expert Rev Anticancer Ther; 2016; 16(2):189-98. PubMed ID: 26618756
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
17. The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer.
Onishi T; Sekito S; Shibahara T; Uchida K; Sasaki T
Scand J Urol; 2018; 52(5-6):385-388. PubMed ID: 30628540
[TBL] [Abstract][Full Text] [Related]
18. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID
BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129
[TBL] [Abstract][Full Text] [Related]
19. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
Paroni R; Salonia A; Lev A; Da Pozzo LF; Cighetti G; Montorsi F; Rigatti P; Colombo R
Br J Clin Pharmacol; 2001 Sep; 52(3):273-8. PubMed ID: 11560559
[TBL] [Abstract][Full Text] [Related]
20. Predicting factors for recurrence in low-grade Ta primary bladder tumours.
Molina Escudero R; Alvarez Ardura M; Ripalda Ferretti E; Crespo Martínez L; González Avila N; Dorado Valentín M; Páez Borda A
Arch Esp Urol; 2014 Jul; 67(6):541-8. PubMed ID: 25048586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
